drugset / Trial / NCT00162032

A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease

NCT00162032

Phase 3 Completed 445 enrolled Lantheus Medical Imaging
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.

Timeline

Start
2005-08
Primary completion
2010-05
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TECHNETIUM SESTAMIBI Diagnostic / imaging agent

Indications